The Levodopa Market Expected To Witness High Growth Owing To Increasing Parkinson's Disease Prevalence
![]() |
| Levodopa Market |
The levodopa market caters to products that contain levodopa, the main drug
used for the treatment of Parkinson's disease. Levodopa helps in enhancing the
levels of dopamine in the brain. It works by decreasing the motor symptoms
experienced by Parkinson's disease patients. Levodopa crosses the blood-brain
barrier and is converted into dopamine by the dopamine neurons in the brain.
The primary use of levodopa is for relieving the muscle rigidity, tremors, and
slowing of movements in patients suffering from Parkinson's disease.
The global levodopa market is
estimated to be valued at US$ 5.5 Bn in 2024 and is expected to exhibit a CAGR of 9.6% over the forecast period of 2024 to 2030.
Key Takeaways
Key players operating in the levodopa market are Laboratory Corporation of
America Holdings (Covance), IQVIA, Paraxel International Corporation, Syneos
Health, PRA Health Sciences, Charles River Laboratoires International Inc.
(CRL), Pharmaceutical Product Development (PPD), ICON Public Limited
Corporation, Wuxi Apptec, Medpace Holdings, Inc, Medidata Solutions, Inc.,
Theorem Clinical Research, Pharmaron, Envigo, and Clinipace. These players are
focusing on expanding their presence in emerging markets through collaborations
and partnerships.
The key opportunities in the levodopa market include increasing incidence of
Parkinson's disease owing to growing geriatric population. As per estimates,
over 10 million people globally will be suffering from Parkinson's disease by
2040. Moreover, the prevalence of Parkinson's disease increases with age and
majority of new diagnoses are made after 60 years of age. This presents
lucrative growth prospects for players in the levodopa market.
Global expansion remains a key focus area for leading players in the Levodopa
Market Demand. Key companies are investing heavily in emerging markets
like Asia Pacific and Latin America. Growing healthcare infrastructure and
increasing disposable incomes in developing economies will boost the adoption
of levodopa products in these untapped markets. Asia Pacific is anticipated to
witness the fastest CAGR during the forecast period.
Market drivers for the levodopa market include rising geriatric population
globally, increasing cases of Parkinson's disease, and availability of new drug
delivery technologies. However, high costs associated with levodopa therapy and
side effects of prolonged usage are restraining factors. Players are engaged in
developing novel extended-release levodopa products with improved tolerability
and lower dosing frequency.
Market drivers for levodopa include increasing aging population globally which
boosts Parkinson's prevalence. Growing geriatric demographic prone to
Parkinson's disease drives the market. However, high therapy costs and side
effects of long-term levodopa usage pose challenges. Companies develop new
sustained-release levodopa therapies to improve tolerability and compliance.
Segment Analysis
The levodopa market can be segmented based on product type, distribution
channel, and geography. Based on product type, the levodopa market is segmented
into immediate release and controlled release drugs. The controlled release
drugs segment currently dominates the market as it offers better management of
Parkinson's disease symptoms by continuous drug delivery over an extended
period. Controlled release levodopa helps reduce fluctuations in levodopa blood
levels throughout the day.
Global Analysis
North America currently dominates the levodopa market, owing to high awareness
regarding Parkinson's disease treatment and favorable reimbursement policies in
countries like the US and Canada. Asia Pacific is expected to be the fastest
growing regional market during the forecast period due to increasing healthcare
expenditure and a large Parkinson's patient pool. Countries like China and
India are expected to drive growth in Asia Pacific levodopa market. Key market
players are focusing on developing novel drug delivery systems to offer more
effective treatment options for Parkinson's disease.
For More Details On The
Report, Read: https://www.newsstatix.com/the-levodopa-market-is-trending-towards-patient-centric-clinical-trials/

Comments
Post a Comment